Member Info for Jarv55

https://www.youtube.com/watch?v=xhA5v8ix9cM
worth a good listen interesting he says others will come into the field but larger companies are slower possible buy out here down the road to save them time.

tra1 get yourself on twitter lse don't like cross posting of stocks

Paul you must rue the day you were introduced to Zorbas and Gige JacktheNorth is not Leon unless he hired a secretary and to be honest I don't think he is bright enough to do that.

TRA you are going to have to give me a little more than B dm me on twitter @Jarvy55

Lets just remind ourselves why we are here
https://www.offshore-technology.com/projects/barryroe-oil-field-north-celtic-sea-basin/

holding up well what are the price targets here on fda approval?

I thought Woodford was already out is he on the website?

Are you Basil Brush?

personally good to see this being steady no leaky ship buy the dips

How about a cup of tea instead?
https://invst.ly/bev16

will the directors buy now?
nice gaps to fill on the chart

https://invst.ly/bes6m

As a result of the actions taken during 2018, we ended the year in a much stronger position than we started it with a strong leadership team, an appropriate cost base and clear focus on operational execution and customer service to drive increased profitability and cash generation. The refinancing, which was completed post year end, has provided long term funding and means that the Company has no other external debt, as the Loan Notes are held solely by shareholders, and predominantly by the largest shareholders.

so you are saying barclays can't trade this yet get on the blower

patience Flappingchicken
SECURED FIRST COMMERCIAL DEAL ON NDD PLATFORM

Signed commercial research collaboration deal with Novo Nordisk in its core disease area of type-2 diabetes
Important validation of e-therapeutics and its technologies
Business development activities continue with a number of discussions progressing on a range of revenue-generating and value-creating deals



ESTABLISHED PARTNERSHIPS DELIVERING

Further developed network-driven drug discovery ("NDD") platform with a strong focus on the application to generate useful, actionable insight from genomic data
Successful initial work in Parkinson's Disease in collaboration with C4X Discovery identified potential new disease mechanisms
Collaborations with Biorelate and Intellegens have been augmenting core NDD platform capabilities and adding to e-therapeutics' already rich pool of biological data



EXCITING RESULTS DEMONSTRATING POTENTIAL OF NDD PLATFORM TO TRANSFORM DRUG DISCOVERY

In-house work on patient segment-specific NDD work in breast cancer delivered promising results
Application of NDD platform to highly industry-relevant target deconvolution and mechanism of action (MoA) work on complex diseases
Creation of new Genome Associated Interaction Networks ("GAINs") functionality to better understand population genetic data



PROGRESS ON EXISTING AND NEW DISCOVERY PROGRAMMES IN COMPLEX DISEASES WHERE THERE IS SIGNIFICANT UNMET NEED

Continued progress on two immuno-oncology programmes driving external discussions on capital efficient means to fund further work
Creation of new partner-ready programmes in neurodegeneration, fibrosis and tumour microenvironment also driving business development discussions

lol follows sarcasm

antofelli you really are a hoot

I think with all the corruption at Mrs John has been taken to task and needs to do things by the book until the heat dies down.
As for him selling Mrs shares why would he do that? They are supposed to be getting a deal worth 10 million from the drone business according to John.

The King I think they will sell it and back some thing else in here

The Company also announces that it has issued and allotted 20,000,000 new ordinary shares following the exercise of warrants granted to Adam International Investments Limited ("Adam International") in January 2017 at an exercise price of 1p per share (the "Warrant Exercise Shares"). The Company engaged Adam International on 1 November 2016 to provide corporate services in relation to the fundraisings subsequently completed by the Company in November 2016 (at a price of 0.4p per share) and January 2017 (at a price of 0.45p per share), and technical consulting services in relation to the work programme, budget and operations of the Company's Nickel projects in South Africa.

So the technical consultants have left the building along with Umnex I can't see them taking Zeb any further exploration wise

Nice close setting up for a break out of the bull flag.